Overview
A Pilot Study of the Safety of MC-1101 in Both Normal Volunteers and Patients With Early Dry AMD
Status:
Completed
Completed
Trial end date:
2009-08-01
2009-08-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The safety and comfort of repeated administrations of a topically-administered ophthalmic formulation of MC-1101 will be established through investigator assessments and subject reporting over a 3 day period. Safety assessments will be performed on both normal, healthy subjects as well as those with the signs and symptoms of early non-exudative age-related macular degeneration (dry AMD).Phase:
Phase 1Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
MacuCLEAR, Inc.
Criteria
Inclusion Criteria:- Clinical diagnosis of dry AMD or;
- Normal, healthy volunteer
Exclusion Criteria:
- Uncontrolled systemic disease
- Women who are pregnant, nursing, or planning a pregnancy during the study's duration